Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
4th quarter beat estimates by a few million. GWPH is ahead of all pharmaceuticals in the CBD industry. Their revenue is likely to increase this year. A lot more buyers than sellers on level 2.
Must have been good news 4th quart report??
Do your homework. Ave cost per patient is around $30k a year. Average copay is probably about $50-$60 a month. Out of pocket for BS OTC CBD is about $300-$400 a month. It’s what insurance is for, to help pay for drugs.
Man.....How much are they charging each poor epileptic ?
60 grand per year ?
Wouldn't 108 million divided by 60 g/y = the # of their patients ?
Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales
Based on preliminary unaudited financial information, the company expects total net product sales to be approximately $108 million for the fourth quarter and approximately $309 million for the year ended December 31, 2019. Total net product sales of Epidiolex are expected to be approximately $104 million for the fourth quarter and approximately $296 million for the full year. Cash and cash equivalents at December 31, 2019 were approximately $536 million. Fourth quarter and full-year 2019 financial results are expected to be reported on February 25th, 2020.
https://finance.yahoo.com/news/gw-pharmaceuticals-pre-announces-preliminary-230010269.html?.tsrc=rss
A multiple sclerosis patient who was facing jail for growing cannabis to ease her pain was acquitted today after the case against her collapsed.
Lesley Gibson, 55, and her husband, Mark, received not guilty verdicts at Carlisle Crown Court after being charged for possession and cultivation of the class B drug.
Their home was raided in January last year with police confiscating ten baby cannabis plants and three home-made cannabis chocolate bars. If convicted the pair faced up to five years in prison or an unlimited fine or both.
Medical cannabis has been legal in Britain for more than a year but only under strict conditions. The difficulty of obtaining an NHS prescription means tens of thousands of patients are still using the black market to get the drug.
The MS Society estimates that 10,000 MS patients use cannabis to alleviate muscle spasticity and pain but campaigners say only a handful have so far been prescribed the drug legally.
Two months ago, the National Institute for Health and Care Excellence (Nice) approved a cannabis-based treatment for MS called Sativex but the NHS will only offer it to those with “moderate to severe” spasticity which has not improved while taking other treatments. https://www.thetimes.co.uk/edition/news/ms-patient-who-grew-cannabis-to-ease-her-pain-is-acquitted-on-drug-charges-jr65qrhmg
Mad Money’s Jim Cramer Says This Cannabis Stock is a Long-Term Hold
CLick here for link
analysts shmanalysts
Financial Times share price forecasts (02-Jan-2020)
The 15 analysts offering 12 month price targets for GW Pharmaceuticals PLC- ADR have a median target of 200.00, with a high estimate of 260.00 and a low estimate of 160.00. The median estimate represents a 91.28% increase from the last price of 104.56.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=GWPH:NMQ
Horizons Rebalances its Cannabis ETFs, Here’s What You Need to Know
https://www.thecannabisinvestor.ca/horizons-rebalances-its-cannabis-etfs-heres-what-you-need-to-know/
Huge news.... this will help thousands upon thousands sufferers in the United Kingdom... and (IMO) this will bob on into Europe once the UK is fast-tracking it... we could see big GW moves in Europe early next year...
Cannabis-based drug for epilepsy to be fast-tracked into NHS
Epidiolex will be available from 6 January after NHS deal with manufacturer
Sarah Boseley
Sat 21 Dec 2019 01.00 EST
Cannabis-based medicine is to be fast-tracked into the NHS, allowing thousands of people to be prescribed the drugs, including children with severe epilepsy.
Last month the NHS struck a deal with the manufacturer GW Pharmaceuticals to bring down the price of Epidiolex, which has been approved by the European medicines agency for use in children over the age of two who suffer from seizures associated with two rare and severe forms of epilepsy – Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
NHS England has said it will speed the process through so that the drugs will be obtainable through doctors from 6 January.
Clinical trials have shown the treatment could reduce the number of seizures by up to 40% in some children when used in combination with another drug, Clobazam. It is estimated that 2,000 people a year could benefit.
The move will not end the calls for cannabis-based medicines to be made easily available on the NHS for people with other conditions. Sativex, GW’s cannabis-based medicine for multiple sclerosis, has been rejected because of its high price, to the dismay of patients and campaigners. Others have unsuccessfully campaigned for approval of cannabis medicines to relieve pain.
This year NHS England published a review of when it is safe and appropriate to consider prescribing unlicensed cannabis-based medicines. But it has become apparent that doctors are unwilling to take the responsibility without more evidence on the effects and safety.
The new twice-daily drug is licensed in both the US and Europe. It contains plant-derived, strawberry-flavoured cannabidiol but not THC, which is responsible for the high from smoked cannabis.
“The NHS is committed, through the Long Term Plan, to improving the lives of all those affected by rare diseases,” said Simon Stevens, the NHS England chief executive. “Living with or caring for someone with severe epilepsy is exceptionally challenging, especially as there are so few treatments available for the rare forms of the condition. Thousands of people including children will now have access to this treatment, which has the potential to make a real difference.”
Wow, huge, fast tracked to beginning of year. Huge news for GWPH heading in to the new year.
Thanks for the update.
Cannabis-based drug for epilepsy Epidiolex to be fast-tracked from 6 January into NHS after NHS deal with manufacturer, allowing thousands of people to be prescribed the drugs, including children with severe epilepsy.
Last month the NHS struck a deal with the manufacturer GW Pharmaceuticals to bring down the price of Epidiolex, which has been approved by the European medicines agency for use in children over the age of two who suffer from seizures associated with two rare and severe forms of epilepsy – Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
NHS England has said it will speed the process through so that the drugs will be obtainable through doctors from 6 January.
https://www.theguardian.com/society/2019/dec/21/cannabis-based-drug-for-epilepsy-to-be-fast-tracked-into-nhs
GW Pharmaceuticals plc GWPH focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.
The cannabinoid drug maker is expected to see an uptick in sales next year as well, especially, after its lead drug; Epidiolex became the first cannabis-derived drug to gain FDA approval.
GW Pharmaceuticals currently has a Zacks Rank #3. The company’s expected earnings growth rate for the next quarter is 69.64% versus the Medical - Products industry’s expected rise of 69.37%.
https://finance.yahoo.com/news/4-marijuana-stocks-play-green-125412989.html
(Thanks to Funman for posting this on another (Aphria) board...)
Why Investors Should be Bullish About GW Pharmaceuticals (GWPH)
https://stocknews.com/news/gwph-why-investors-should-be-bullish-gw-pharmaceuticals-gwph/
It did! That's one hurdle out of the way. Next goal, above $114.50
$107+ = full breakout now..
Financial Times share price forecasts (13-Dec-2019)
GWPH
The 15 analysts offering 12 month price targets for GW Pharmaceuticals PLC- ADR have a median target of 200.00, with a high estimate of 260.00 and a low estimate of 160.00. The median estimate represents a 89.21% increase from the last price of 105.70. ($US)
well let's hope it does that tomorrow.
Honestly it isn't. It's just trading in a range. Last week it hit $106.95. A start would be getting above last weeks high
looking good today...
I dipped not a toe in, but rather a big foot... it's the way I do life.... full on.... and happy enough with the 6% share price rise at the moment...
Looks like right was right. LMFAO.
Long term support around $90. If it goes below that, I'd be looking for somewhere around $82 perhaps.
Otherwise, the play here is to dip your toe in now and build.
Ooops.... I am down on my recent entry to GW Pharma... but I will stay long here, especially after seeing the Financial Times this morning:
Share price forecast (10-December-2019)
The 15 analysts offering 12 month price targets for GW Pharmaceuticals PLC- ADR have a median target of 200.00, with a high estimate of 260.00 and a low estimate of 160.00. The median estimate represents a 108.12% increase from the last price of 96.10.
Agree, patience and $ cost averaging down here, it will turn on a dime and move north heading in to 2020. Big year ahead.
Close to $300 mil in year one sales when wall street forecast was what $125 mil? This will move up hard in 2020. Europe takes off, TSC in the US, this is a gift.
Dog poop.. buy out wouldn’t even move this pos
The value is the value. Excuses mean nothing. And wrong is wrong.
Have to love those constant algo 100 share trades just taking it lower, legit eh?
Would really hate to see it below $95.71 for the week.
Not worried, I have been dollar cost averaging here for a few months. Long term hold so the longer it stays down short term is fine with me. Let's review where the PPS is a few months from now
The opposite occurred
Looking for a nice close in to weekend and Monday's events.
you'll be happy to know I see up next week.
While some make outrageous promises, I read charts. You each get to decide which is more useful.
I care more about forecasting earnings than guessing at prices. How often are they wrong? And, if you know anything about analysts, they change their mind on a whim.
Great things coming, 2020 and beyond:
https://seekingalpha.com/article/4310837?source=partner_djnw
But it’s got to see $70 first hahaha!
I think tomorrow will be a big day as results coming out this weekend if positive are not built in to the share price. Plus all the alogos played here few weeks keeping this down are in for a rude awakening.
Many great weeks ahead for GWPH.
Stock Price Forecast
The 15 analysts offering 12-month price forecasts for GW Pharmaceuticals PLC have a median target of 200.00, with a high estimate of 260.00 and a low estimate of 160.00. The median estimate represents a +93.20% increase from the last price of 103.52.
They will get smoked tomorrow leading in to weekend event and then Monday will be a nice breakthrough imo.
“And we’re about to launch the drug in Europe as well.”
Selling now because why?
Oh right bc algos got it
Followers
|
256
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5918
|
Created
|
04/18/13
|
Type
|
Free
|
Moderators |
GWPH Analyst Stock Ratings:
Citigroup - Target Cut from $97 to $86 - 6/30/14
Morgan Stanley - Overweight - $103 - 5/19/14 (Restated) 4/22/14 (Initiated)
Bank of America - Buy - $110 - 3/11/14
Piper Jaffray - Overweight - $147 - 6/30/14
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |